Do antidepressant advertisements educate consumers and promote communication between patients with depression and their physicians?

Bell, Robert A.; Taylor, Laramie D.; Kravitz, Richard L.

doi:10.1016/j.pec.2010.01.014

Cited by 25 publications

(23 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Kaiser Foundation and Harvard School of Public Health survey concluded that onethird (32%) of Americans had talked to their physician about an advertised medication (Kaiser Family Foundation, 2008). However, others have reported lower rates of requests, from 13% (Bell et al, 2010;Deshpande et al, 2004) to 10% or less Parnes et al, 2009).…”

Section: -2012mentioning

confidence: 94%

“…Patient reports of whether they discussed or requested a particular medication that they saw advertised continued to vary. Such conversations increased slightly and ranged from 39.9% to 42% (Bell, Taylor, & Kravitz, 2010;Deshpande, Menon, Perri, & Zinkhan, 2004). A Kaiser Foundation and Harvard School of Public Health survey concluded that onethird (32%) of Americans had talked to their physician about an advertised medication (Kaiser Family Foundation, 2008).…”

Section: -2012mentioning

confidence: 99%

“…Since then, physician attitudes have trended more neutral about DTCA (Tentler, Silberman, Paterniti, Kravitz, & Epstein, 2007), while rates of prescribing have increased in response to patient requests (Gu, Dillon, & Burt, 2010). Skepticism among consumers about the value of DTCA has also risen in the past few years (Bell, Taylor, & Kravitz, 2010). Moreover, heavily advertised medications (e.g., Vioxx) have been subject to recalls and challenges about advertising claims.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Then and Now: Examining How Consumer Communication and Attitudes of Direct-to-Consumer Pharmaceutical Advertising Have Changed in the Last Decade

Wood

Cronley

2013

Health Communication

View full text Add to dashboard Cite

This study examines changes over a 10-year period in consumer reports of communication with health care providers about direct-to-consumer advertised (DTCA) medications. Two rounds of survey data were collected in 2003 and 2012 using repeated cross-sectional procedures to examine consumer willingness to discuss DTCA medications, content and tone of those conversations, and attitudes about the advertisements. In total, 472 surveys were analyzed. Generally, we found physician-patient conversations, attitudes, and behaviors regarding DTCA have changed. Consumers in 2012 reported talking significantly less about the names of the advertised drug, comparing the advertised drug with their current medication, and sharing general information than consumers in 2003. Attitudes toward the advertisements were significantly more negative in 2012 compared to 2003. Of those who specifically asked for a prescription, the proportion of patients who received the prescription was significantly lower in 2012, despite research suggesting increased rates of prescriptions. These results are interpreted in light of previous research about the lack of research examining the actual communication between physicians and patients on this topic. Limitations of the study are provided along with directions for future research about DTCA and physician-patient communication.

show abstract

Section: -2012mentioning

confidence: 94%

Section: -2012mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Then and Now: Examining How Consumer Communication and Attitudes of Direct-to-Consumer Pharmaceutical Advertising Have Changed in the Last Decade

Wood

Cronley

2013

Health Communication

View full text Add to dashboard Cite

show abstract

“…In recent years, health and policy scholars have devoted increased attention to online medication sites in order to understand how they may affect people's health-related beliefs and behaviors (e.g., Bell, Taylor & Kravitz, 2010;Calfee, 2007;Donohue & Berndt, 2004;Kim & Seong, 2010). Within this program of research, a growing number of empirical studies have found direct-to-consumer advertisement (DTCA) sites may have class-wide effects, meaning that advertisements for prescription medications can increase demand for the advertised drug as well as the demand for related medications (Atherly & Rubin, 2009;Rosenthal, Berndt, Donohue, Epstein, & Frank, 2003).…”

Section: Introductionmentioning

confidence: 99%

“…The effects of DTC advertisements have been documented in numerous academic and industry studies, which routinely find positive associations between exposure to DTC advertisements and outcomes such as patientdoctor dialogue (e.g., Bell et al, 2010;Choi & Lee, 2007) increased prospect conversion (Aquino, 2011) and patient refills (Bradley & Zito, 1997). While only a small subset of DTCA researchers has focused specifically on psychiatric treatments, studies examining the effects of DTC advertisements for antidepressant medications have yielded similarly promising findings (e.g., Soontae, Hyun Seung, & Brown, 2009;Donohue & Berndt, 2004).…”

Section: Introductionmentioning

confidence: 99%

Thinking Outside the Medicine Cabinet: A Comparative Content Analysis of Direct-to-Consumer Advertisements for Prescription Drug Treatments

McKeever

2014

Health Marketing Quarterly

View full text Add to dashboard Cite

This study content analyzed online direct-to-consumer advertisements (DTCA) for prescription drug treatments to explore whether ads for prescription treatments for psychiatric conditions, which are commonly untreated, differ from other drug advertisements. Coded variables included the presence of interactive technological components, use of promotional incentives, and the social contexts portrayed in images shown on each site. Statistical analysis revealed ads for psychiatric medications contained fewer interactive website features, financial incentives, and calls to action than other types of prescription drug advertisements. Implications for health communication researchers are discussed.

show abstract

Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

English

Dortch

Ereshefsky

et al. 2012

Curr Psychiatry Rep

View full text Add to dashboard Cite

In recent years, the growing numbers of patients seeking care for a wide range of psychiatric illnesses in the primary care setting has resulted in an increase in the number of psychotropic medications prescribed. Along with the increased utilization of psychotropic medications, considerable variability is noted in the prescribing patterns of primary care providers and psychiatrists. Because psychiatric patients also suffer from a number of additional medical comorbidities, the increased utilization of psychotropic medications presents an elevated risk of clinically significant drug interactions in these patients. While life-threatening drug interactions are rare, clinically significant drug interactions impacting drug response or appearance of serious adverse drug reactions have been documented and can impact long-term outcomes. Additionally, the impact of genetic variability on the psychotropic drug’s pharmacodynamics and/or pharmacokinetics may further complicate drug therapy. Increased awareness of clinically relevant psychotropic drug interactions can aid clinicians to achieve optimal therapeutic outcomes in patients in the primary care setting.

show abstract

Do antidepressant advertisements educate consumers and promote communication between patients with depression and their physicians?

Cited by 25 publications

References 38 publications

Then and Now: Examining How Consumer Communication and Attitudes of Direct-to-Consumer Pharmaceutical Advertising Have Changed in the Last Decade

Then and Now: Examining How Consumer Communication and Attitudes of Direct-to-Consumer Pharmaceutical Advertising Have Changed in the Last Decade

Thinking Outside the Medicine Cabinet: A Comparative Content Analysis of Direct-to-Consumer Advertisements for Prescription Drug Treatments

Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

Contact Info

Product

Resources

About